1
|
Haile PA, Casillas LN, Bury MJ, Mehlmann JF, Singhaus R, Charnley AK, Hughes TV, DeMartino MP, Wang GZ, Romano JJ, Dong X, Plotnikov NV, Lakdawala AS, Duraiswami C, Convery MA, Votta BJ, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, LePage C, Ouellette MT, Totoritis RD, Donovan BT, Brown BS, Chaudhary KW, Gough PJ, Bertin J, Marquis RW. Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel. ACS Med Chem Lett 2020; 11:1353. [PMID: 32551024 DOI: 10.1021/acsmedchemlett.0c00260] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
[This corrects the article DOI: 10.1021/acsmedchemlett.8b00344.].
Collapse
|
2
|
Haffner CD, Charnley AK, Aquino CJ, Casillas L, Convery MA, Cox JA, Elban MA, Goodwin NC, Gough PJ, Haile PA, Hughes TV, Knapp-Reed B, Kreatsoulas C, Lakdawala AS, Li H, Lian Y, Lipshutz D, Mehlmann JF, Ouellette M, Romano J, Shewchuk L, Shu A, Votta BJ, Zhou H, Bertin J, Marquis RW. Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors. ACS Med Chem Lett 2019; 10:1518-1523. [PMID: 31749904 DOI: 10.1021/acsmedchemlett.9b00141] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 09/26/2019] [Indexed: 12/30/2022] Open
Abstract
Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant kinase selectivity and potency were achieved. Bridged bicyclic pyrazolocarboxamide 11 represents a selective and potent inhibitor of RIP2 and will allow for a more detailed investigation of RIP2 inhibition as a therapeutic target for autoinflammatory disorders.
Collapse
Affiliation(s)
- Curt D. Haffner
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Adam K. Charnley
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | | | - Linda Casillas
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Máire A. Convery
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, U.K
| | - Julie A. Cox
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Mark A. Elban
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Nicole C. Goodwin
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Peter J. Gough
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Pamela A. Haile
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | | | - Beth Knapp-Reed
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Constantine Kreatsoulas
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Ami S. Lakdawala
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Huijie Li
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Yiqian Lian
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - David Lipshutz
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - John F. Mehlmann
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Michael Ouellette
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Joseph Romano
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Lisa Shewchuk
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Arthur Shu
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Bartholomew J. Votta
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Huiqiang Zhou
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - John Bertin
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Robert W. Marquis
- GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States
| |
Collapse
|
3
|
Haile PA, Casillas LN, Votta BJ, Wang GZ, Charnley AK, Dong X, Bury MJ, Romano JJ, Mehlmann JF, King BW, Erhard KF, Hanning CR, Lipshutz DB, Desai BM, Capriotti CA, Schaeffer MC, Berger SB, Mahajan MK, Reilly MA, Nagilla R, Rivera EJ, Sun HH, Kenna JK, Beal AM, Ouellette MT, Kelly M, Stemp G, Convery MA, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Marquis RW. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[ d]thiazol-5-ylamino)-6-( tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem 2019; 62:6482-6494. [PMID: 31265286 DOI: 10.1021/acs.jmedchem.9b00575] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
RIP2 kinase has been identified as a key signal transduction partner in the NOD2 pathway contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP2 kinase or its signaling partners on the NOD2 pathway that are suitable for advancement into the clinic have yet to be described. Herein, we report our discovery and profile of the prodrug clinical compound, inhibitor 3, currently in phase 1 clinical studies. Compound 3 potently binds to RIP2 kinase with good kinase specificity and has excellent activity in blocking many proinflammatory cytokine responses in vivo and in human IBD explant samples. The highly favorable physicochemical and ADMET properties of 3 combined with high potency led to a predicted low oral dose in humans.
Collapse
Affiliation(s)
- Pamela A Haile
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Linda N Casillas
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Bartholomew J Votta
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Gren Z Wang
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Adam K Charnley
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Xiaoyang Dong
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Michael J Bury
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Joseph J Romano
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - John F Mehlmann
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Bryan W King
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Karl F Erhard
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Charles R Hanning
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - David B Lipshutz
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Biva M Desai
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Carol A Capriotti
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Michelle C Schaeffer
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Scott B Berger
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Mukesh K Mahajan
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Michael A Reilly
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Rakesh Nagilla
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Elizabeth J Rivera
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Helen H Sun
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - John K Kenna
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Allison M Beal
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Michael T Ouellette
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Mike Kelly
- GlaxoSmithKline , Gunnels Wood Road , Stevenage , Hertfordshire SG1 2NY , U.K
| | - Gillian Stemp
- GlaxoSmithKline , Gunnels Wood Road , Stevenage , Hertfordshire SG1 2NY , U.K
| | - Máire A Convery
- GlaxoSmithKline , Gunnels Wood Road , Stevenage , Hertfordshire SG1 2NY , U.K
| | - Anna Vossenkämper
- Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry , Queen Mary University of London , London E1 2AD , U.K
| | - Thomas T MacDonald
- Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry , Queen Mary University of London , London E1 2AD , U.K
| | - Peter J Gough
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - John Bertin
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| | - Robert W Marquis
- GlaxoSmithKline , Collegeville Road , Collegeville , Pennsylvania 19426 , United States
| |
Collapse
|
4
|
Haile PA, Casillas LN, Bury MJ, Mehlmann JF, Singhaus R, Charnley AK, Hughes TV, DeMartino MP, Wang GZ, Romano JJ, Dong X, Plotnikov NV, Lakdawala AS, Convery MA, Votta BJ, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, LePage C, Ouellette MT, Totoritis RD, Donovan BT, Brown BS, Chaudhary KW, Gough PJ, Bertin J, Marquis RW. Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel. ACS Med Chem Lett 2018; 9:1039-1044. [PMID: 30344914 DOI: 10.1021/acsmedchemlett.8b00344] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Accepted: 09/11/2018] [Indexed: 12/25/2022] Open
Abstract
RIP2 kinase was recently identified as a therapeutic target for a variety of autoimmune diseases. We have reported previously a selective 4-aminoquinoline-based RIP2 inhibitor GSK583 and demonstrated its effectiveness in blocking downstream NOD2 signaling in cellular models, rodent in vivo models, and human ex vivo disease models. While this tool compound was valuable in validating the biological pathway, it suffered from activity at the hERG ion channel and a poor PK/PD profile thereby limiting progression of this analog. Herein, we detail our efforts to improve both this off-target liability as well as the PK/PD profile of this series of inhibitors through modulation of lipophilicity and strengthening hinge binding ability. These efforts have led to inhibitor 7, which possesses high binding affinity for the ATP pocket of RIP2 (IC50 = 1 nM) and inhibition of downstream cytokine production in human whole blood (IC50 = 10 nM) with reduced hERG activity (14 μM).
Collapse
Affiliation(s)
- Pamela A. Haile
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Linda N. Casillas
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Michael J. Bury
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - John F. Mehlmann
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Robert Singhaus
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Adam K. Charnley
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Terry V. Hughes
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Michael P. DeMartino
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Gren Z. Wang
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Joseph J. Romano
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Xiaoyang Dong
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Nikolay V. Plotnikov
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Ami S. Lakdawala
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Maire A. Convery
- GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom
| | - Bartholomew J. Votta
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - David B. Lipshutz
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Biva M. Desai
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Barbara Swift
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Carol A. Capriotti
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Scott B. Berger
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Mukesh K. Mahajan
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Michael A. Reilly
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Elizabeth J. Rivera
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Helen H. Sun
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Rakesh Nagilla
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Carol LePage
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Michael T. Ouellette
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Rachel D. Totoritis
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Brian T. Donovan
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Barry S. Brown
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Khuram W. Chaudhary
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Peter J. Gough
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - John Bertin
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| | - Robert W. Marquis
- GlaxoSmithKline, Collegeville Road, Collegeville, Pennsylvania 19426, United States
| |
Collapse
|
5
|
Haile PA, Votta BJ, Marquis RW, Bury MJ, Mehlmann JF, Singhaus R, Charnley AK, Lakdawala AS, Convery MA, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, Beal AM, Finger JN, Cook MN, King BW, Ouellette MT, Totoritis RD, Pierdomenico M, Negroni A, Stronati L, Cucchiara S, Ziółkowski B, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Casillas LN. The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase. J Med Chem 2016; 59:4867-80. [PMID: 27109867 DOI: 10.1021/acs.jmedchem.6b00211] [Citation(s) in RCA: 76] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
RIP2 kinase is a central component of the innate immune system and enables downstream signaling following activation of the pattern recognition receptors NOD1 and NOD2, leading to the production of inflammatory cytokines. Recently, several inhibitors of RIP2 kinase have been disclosed that have contributed to the fundamental understanding of the role of RIP2 in this pathway. However, because they lack either broad kinase selectivity or strong affinity for RIP2, these tools have only limited utility to assess the role of RIP2 in complex environments. We present, herein, the discovery and pharmacological characterization of GSK583, a next-generation RIP2 inhibitor possessing exquisite selectivity and potency. Having demonstrated the pharmacological precision of this tool compound, we report its use in elucidating the role of RIP2 kinase in a variety of in vitro, in vivo, and ex vivo experiments, further clarifying our understanding of the role of RIP2 in NOD1 and NOD2 mediated disease pathogenesis.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Máire A Convery
- Platform Technology and Science, GlaxoSmithKline, Medicines Research Centre , Stevenage, SG1 2NY, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Maria Pierdomenico
- Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) , 00196 Rome, Italy
| | - Anna Negroni
- Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA) , 00196 Rome, Italy
| | - Laura Stronati
- Department of Cellular Biotechnology and Hematology, Sapienza University Hospital Umberto I , 00161 Rome, Italy
| | - Salvatore Cucchiara
- Department of Pediatrics, Pediatric Gastroenterology and Liver Unit, Sapienza University Hospital Umberto I , 00161 Rome, Italy
| | | | - Anna Vossenkämper
- Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London , E1 2AD London, U.K
| | - Thomas T MacDonald
- Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London , E1 2AD London, U.K
| | | | | | | |
Collapse
|
6
|
Crawley ML, Phipps KM, Goljer I, Mehlmann JF, Lundquist JT, Ullrich JW, Yang C, Mahaney PE. Efficient, regioselective palladium-catalyzed tandem Heck-isomerization reaction of aryl bromides and non-allylic benzyl alcohols. Org Lett 2010; 11:1183-5. [PMID: 19209924 DOI: 10.1021/ol900036y] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
An efficient and mild method to couple aryl bromides and activated non-allylic alcohols in a Heck reaction with tandem isomerization to selectively afford high yields of 1,5-diarylalkan-1-ones has been developed. Mechanistic insight was gained through NMR studies of products derived from deuterium-labeled intermediates.
Collapse
Affiliation(s)
- Matthew L Crawley
- Discovery Medicinal Chemistry, Chemical Sciences, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Vera MD, Lundquist JT, Chengalvala MV, Cottom JE, Feingold IB, Garrick LM, Green DM, Hauze DB, Mann CW, Mehlmann JF, Rogers JF, Shanno L, Wrobel JE, Pelletier JC. Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem Lett 2010; 20:2512-5. [DOI: 10.1016/j.bmcl.2010.02.099] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2010] [Accepted: 02/26/2010] [Indexed: 10/19/2022]
|
8
|
Lundquist JT, Harnish DC, Kim CY, Mehlmann JF, Unwalla RJ, Phipps KM, Crawley ML, Commons T, Green DM, Xu W, Hum WT, Eta JE, Feingold I, Patel V, Evans MJ, Lai K, Borges-Marcucci L, Mahaney PE, Wrobel JE. Improvement of physiochemical properties of the tetrahydroazepinoindole series of farnesoid X receptor (FXR) agonists: beneficial modulation of lipids in primates. J Med Chem 2010; 53:1774-87. [PMID: 20095622 DOI: 10.1021/jm901650u] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
In an effort to develop orally active farnesoid X receptor (FXR) agonists, a series of tetrahydroazepinoindoles with appended solubilizing amine functionalities were synthesized. The crystal structure of the previously disclosed FXR agonist, 1 (FXR-450), aided in the design of compounds with tethered solubilizing functionalities designed to reach the solvent cavity around the hFXR receptor. These compounds were soluble in 0.5% methylcellulose/2% Tween-80 in water (MC/T) for oral administration. In vitro and in vivo optimization led to the identification of 14dd and 14cc, which in a dose-dependent fashion regulated low density lipoprotein cholesterol (LDLc) in low density lipoprotein receptor knockout (LDLR(-/-)) mice. Compound 14cc was dosed in female rhesus monkeys for 4 weeks at 60 mg/kg daily in MC/T vehicle. After 7 days, triglyceride (TG) levels and very low density lipoprotein cholesterol (VLDLc) levels were significantly decreased and LDLc was decreased 63%. These data are the first to demonstrate the dramatic lowering of serum LDLc levels by a FXR agonist in primates and supports the potential utility of 14cc in treating dyslipidemia in humans beyond just TG lowering.
Collapse
Affiliation(s)
- Joseph T Lundquist
- Department of Chemical Sciences, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Pelletier JC, Lundquist JT, Gilbert AM, Alon N, Bex FJ, Bhat BM, Bursavich MG, Coleburn VE, Felix LA, Green DM, Green P, Hauze DB, Kharode YP, Lam HS, Lockhead SR, Magolda RL, Matteo JJ, Mehlmann JF, Milligan C, Murrills RJ, Pirrello J, Selim S, Sharp MC, Unwalla RJ, Vera MD, Wrobel JE, Yaworsky P, Bodine PVN. (1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: A Wingless β-Catenin Agonist That Increases Bone Formation Rate. J Med Chem 2009; 52:6962-5. [DOI: 10.1021/jm9014197] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Affiliation(s)
| | | | - Adam M. Gilbert
- Chemical Sciences, Wyeth Research, 401 N. Middletown Road, Pearl River, New York 10965
| | - Nipa Alon
- Chemical Sciences, Wyeth Research, 401 N. Middletown Road, Pearl River, New York 10965
| | | | | | - Mattew G. Bursavich
- Chemical Sciences, Wyeth Research, 401 N. Middletown Road, Pearl River, New York 10965
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Hauze DB, Chengalvala MV, Cottom JE, Feingold IB, Garrick L, Green DM, Huselton C, Kao W, Kees K, Lundquist JT, Mann CW, Mehlmann JF, Rogers JF, Shanno L, Wrobel J, Pelletier JC. Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: Structure–activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template. Bioorg Med Chem Lett 2009; 19:1986-90. [DOI: 10.1016/j.bmcl.2009.02.043] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2008] [Revised: 02/09/2009] [Accepted: 02/10/2009] [Indexed: 11/25/2022]
|
11
|
Pelletier JC, Chengalvala MV, Cottom JE, Feingold IB, Green DM, Hauze DB, Huselton CA, Jetter JW, Kopf GS, Lundquist JT, Magolda RL, Mann CW, Mehlmann JF, Rogers JF, Shanno LK, Adams WR, Tio CO, Wrobel JE. Discovery of 6-({4-[2-(4-tert-Butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): An Orally Active Antagonist of the Gonadotropin Releasing Hormone Receptor (GnRH-R). J Med Chem 2009; 52:2148-52. [DOI: 10.1021/jm801572m] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Jeffrey C. Pelletier
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Murty V. Chengalvala
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Joshua E. Cottom
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Irene B. Feingold
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Daniel M. Green
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Diane B. Hauze
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Christine A. Huselton
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - James W. Jetter
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Gregory S. Kopf
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Joseph T. Lundquist
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Ronald L. Magolda
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Charles W. Mann
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - John F. Mehlmann
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - John F. Rogers
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Linda K. Shanno
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - William R. Adams
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Cesario O. Tio
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| | - Jay E. Wrobel
- Department of Chemical Sciences, Musculoskeletal Biology, and Drug Safety and Metabolism, Wyeth Research, 500 Arcola Road, Collegeville, Pennsylvania 19426
| |
Collapse
|
12
|
Crawley ML, Goljer I, Jenkins DJ, Mehlmann JF, Nogle L, Dooley R, Mahaney PE. Regioselective Synthesis of Substituted Pyrroles: Efficient Palladium-Catalyzed Cyclization of Internal Alkynes and 2-Amino-3-iodoacrylate Derivatives. Org Lett 2006; 8:5837-40. [PMID: 17134285 DOI: 10.1021/ol062424p] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The first efficient and regioselective palladium-catalyzed cyclization of internal alkynes and 2-amino-3-iodoacrylates to give moderate to excellent yields of highly functionalized pyrroles has been developed. This approach is applicable to a range of alkynes and affords the deacylated pyrrole under reaction conditions for most substrates. [reaction: see text]
Collapse
Affiliation(s)
- Matthew L Crawley
- Discovery Medicinal Chemistry and Discovery Analytical Chemistry, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA.
| | | | | | | | | | | | | |
Collapse
|
13
|
Crouch RD, Mehlmann JF, Herb BR, Mitten JV, Dai HG. Selective Conversion of Enol Ethers into Alcohols in the Presence of Alkenes Using Hg(OAc)2-NaBH4. SYNTHESIS-STUTTGART 1999. [DOI: 10.1055/s-1999-3433] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|